Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

59
PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
59
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

433
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
433
Pharmacokinetic–Pharmacodynamic Relationship: Problems01:24

Pharmacokinetic–Pharmacodynamic Relationship: Problems

55
The empirical approach to drug therapy optimization relies on correlating pharmacological response with administered dosage. Such an approach can be costly, time-consuming, and often yields poor correlation due to variables like formulation factors and drug elimination characteristics. A more precise approach correlates response with plasma drug concentration or the amount of drug in the body, rather than dosage. This is achieved through pharmacokinetic-pharmacodynamic (PK/PD) modeling, which...
55
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

245
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
245
Pharmacodynamic Models: Direct Effect Model and Indirect Response Model01:29

Pharmacodynamic Models: Direct Effect Model and Indirect Response Model

80
Pharmacodynamic models are essential tools in understanding the relationship between drug concentrations and their effects on biological systems. By characterizing the dynamics of drug action, these models guide dose selection, optimize therapeutic efficacy, and inform the development of new drugs. Two major classes of pharmacodynamic models include direct effect and indirect response models.Direct Effect ModelsDirect effect models describe the immediate relationship between drug concentration...
80
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

50
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
50

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperleukocytosis and outcomes in pediatric B-cell acute lymphoblastic leukemia: A report from the REDIAL Consortium.

medRxiv : the preprint server for health sciences·2026
Same author

Stability of extemporaneously compounded cobimetinib oral suspensions.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2026
Same author

Impact of Dosing Interval Adherence on Pharmacokinetic Outcomes of Recombinant Erwinia Asparaginase in Pediatric Leukemia or Lymphoma.

Pharmacotherapy·2026
Same author

Advancing non-sterile pediatric pharmacotherapy through automated compounding and 3D printing of ondansetron hcl dihydrate dosage forms.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners·2025
Same author

An analysis of diagnostic metabolomic profiles associated with hepatotoxicity during childhood ALL induction therapy.

Blood advances·2025
Same author

Automated 3D Printing-Based Non-Sterile Compounding Technology for Pediatric Corticosteroid Dosage Forms in a Health System Pharmacy Setting.

Pharmaceutics·2025

Related Experiment Video

Updated: Mar 11, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K

Using decision modeling to guide drug allocation during a shortage.

Heidi V Russell1,2, M Brooke Bernhardt3, Stacey Berg1,2

  • 1Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.

Pediatric Blood & Cancer
|November 19, 2016
PubMed
Summary
This summary is machine-generated.

Drug shortages necessitate difficult allocation decisions. Decision modeling can supplement ethical frameworks, showing efficiency-based distribution saves more lives than first-come, first-served during methotrexate shortages.

Keywords:
chemotherapydecision modeldrug shortageethics

More Related Videos

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Related Experiment Videos

Last Updated: Mar 11, 2026

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
05:10

Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System

Published on: December 11, 2016

10.3K
Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.4K
An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
09:41

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

Published on: July 15, 2015

9.1K

Area of Science:

  • Oncology
  • Pharmacoeconomics
  • Clinical Decision-Making

Background:

  • Drug shortages pose significant challenges for clinical teams in allocating limited medications.
  • Ethical frameworks guide drug distribution but have gaps in clinical application.
  • Decision modeling can enhance ethical frameworks for drug allocation.

Purpose of the Study:

  • To explore decision modeling's role in informing drug distribution during shortages.
  • To compare allocation strategies for methotrexate (MTX) in a pediatric oncology setting.

Main Methods:

  • A hypothetical pediatric oncology clinic scenario was modeled.
  • Limited methotrexate supply (50,000 mg) and 21 patients with varying treatment regimens were simulated.
  • A decision analytic model assessed MTX effectiveness (mg/life year saved) and explored alternative dosing strategies.

Main Results:

  • Total MTX needed was 108,791 mg, exceeding supply.
  • First-come, first-served allocation treated only 7 patients.
  • Efficiency-based allocation treated 19 patients; substituting less effective regimens treated 20 patients.
  • Dose per square meter was the primary efficiency driver.

Conclusions:

  • No allocation strategy completely avoids negative patient outcomes during shortages.
  • Drug efficacy evidence influences decisions on substituting alternative treatments.
  • Efficiency-based allocation and regimen substitution improve patient treatment numbers compared to first-come, first-served.